Anturane TIA Italian Study "ATIAIS"


Phase N/A Results

Trial Description

To assess the relative efficacies of aspirin and sulfinpyrazone in the treatment of patients with TIA.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Sulfinpyrazone (Anturane)Drug
    Intervention Desc: Uricosuric agent, platelet inhibitor, antithrombotic agent.

Trial Design

Stratified, randomized, double-blind trial of 124 patients at 6 centers. Patients were stratified by center.

Patient Involvement

Patients were randomized to receive aspirin (500 mg twice daily) or sulfinpyrazone (400 mg twice daily). Follow-up visits were scheduled 1, 2, 4, and 6 months after commencement of treatment and every three months thereafter for a maximum of two years.


Type Measure Time Frame Safety Issue
Primary Stroke, myocardial infarction, vascular death, and worsening or no improvement of TIAs.